Reify Health, a Boston, Massachusetts-based cloud response provider that connects and strengthens the clinical trial ecosystem, has raised $30 million in Series B funds.

The tour was conducted through Battery Ventures with the participation of previous investors, adding Sierra Ventures and Asset Management Ventures.

The company intends to use budget to expand its StudyTeam directory and drive more platforms.

Led by Ralph Passarella, CEO and co-founder, and Michael Lin, co-founder and chief executive officer, Reify supplies StudyTeam, which allows fitness staff at clinical study sites to upgrade the systems they have for trials. By integrating them into a shared platform with biopharmaceutical sponsors, Reify enables industry players to drive clinical trial recruitment and reduce stakeholder workload across the ecosystem. StudyTeam systematically removes redundant paints from the clinical trial procedure while generating new data that accelerates trials. The platform is used through 1,800 research sites in 26 countries and through part of the world’s 20 largest biopharmaceutical companies, as well as Eli Lilly and Company and Amgen.

FinSME

08/12/2020